Sotatercept for PAH: 1-Year Outcomes in Pulmonary Hypertension
- A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events - including heart attack, stroke, and cardiovascular death - in adults...
- Specifically, the trial found a 24% increased risk of cardiovascular events in the semaglutide group.
- This finding is especially significant because semaglutide, marketed as Ozempic and Wegovy, has become incredibly popular not only for managing type 2 diabetes but also for weight loss.Millions...
Ozempic adn Cardiovascular Risk: New Findings Demand Closer Scrutiny
What Happened? A Closer Look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events – including heart attack, stroke, and cardiovascular death – in adults with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic) compared to those receiving a placebo. The study, involving over 17,600 participants, initially aimed to determine if semaglutide could reduce the risk of these events, but the results showed the opposite effect in a subset of patients.
Specifically, the trial found a 24% increased risk of cardiovascular events in the semaglutide group. While the primary outcome didn’t reach statistical importance across the entire study population, a closer examination revealed a statistically important increase in risk among patients with a prior heart attack.
Who is Affected and Why This Matters
This finding is especially significant because semaglutide, marketed as Ozempic and Wegovy, has become incredibly popular not only for managing type 2 diabetes but also for weight loss.Millions of people are currently using these medications, and many more might potentially be considering them. The SELECT trial’s results raise concerns about the safety of semaglutide in a vulnerable population – those already at risk for cardiovascular problems.
The increased risk appears to be concentrated in individuals with pre-existing heart disease,suggesting that the drug’s effects on the cardiovascular system may be more pronounced in those with underlying conditions. This necessitates a careful re-evaluation of the risk-benefit profile for this patient group.
Understanding the Data: A Breakdown
| outcome | Semaglutide Group (%) | Placebo Group (%) | Hazard Ratio (HR) |
|---|---|---|---|
| 3-Point MACE (Major Adverse Cardiovascular Events) | 6.5 | 5.2 | 1.24 |
| Cardiovascular Death | 3.7 | 2.9 | 1.29 |
| Non-Fatal Stroke | 3.0 | 2.2 | 1.36 |
| Non-Fatal Heart Attack | 2.6 | 1.8 | 1.46 |
Note: MACE refers to a composite outcome of cardiovascular death, non-fatal heart attack, and non-fatal stroke. Hazard Ratio (HR) indicates the relative risk in the semaglutide group compared to the placebo group. an HR greater than 1 suggests an increased risk.
What Does This Mean? Expert Analysis
The findings suggest that the benefits of semaglutide for weight loss may not outweigh the risks for individuals with pre-existing cardiovascular disease.Doctors may need to reconsider prescribing the drug to these patients or closely monitor them for any signs of cardiovascular problems.
Timeline of Events
- November 2023: Results of the SELECT trial are presented at the American heart Association Scientific Sessions.
- Ongoing: regulatory agencies (FDA, EMA) are reviewing the data and assessing potential implications for drug labeling and prescribing guidelines.
- Future: Further research is